<DOC>
	<DOCNO>NCT01104259</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together cisplatin vinorelbine ditartrate treat patient breast cancer return spread part body . Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin vinorelbine ditartrate , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving veliparib together combination chemotherapy may better treatment breast cancer .</brief_summary>
	<brief_title>Veliparib , Cisplatin , Vinorelbine Ditartrate Treating Patients With Recurrent and/or Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) ABT-888 ( veliparib ) administer daily 14 day 21 day cycle combination cisplatin vinorelbine ( vinorelbine ditartrate ) subject metastatic triple negative breast cancer ( TNBC ) breast cancer ( BRCA ) mutation associate breast cancer . SECONDARY OBJECTIVES : I. Assess pharmacokinetic profile ABT-888 combine cisplatin vinorelbine safety/tolerability profile combination . II . Evaluate level poly ADP ribose polymerase ( PARP ) inhibition dose level determine whether maximal PARP inhibition achieve . III . Identify subgroup triple negative breast cancer patient potentially derive benefit PARP inhibition combine platinum-based chemotherapy . OUTLINE : This dose-escalation study veliparib . Patients receive veliparib orally ( PO ) twice daily ( BID ) day 1-14 ( day 0-13 course 1 ) . Patients also receive cisplatin intravenously ( IV ) 1 hour day 1 vinorelbine ditartrate IV 10-20 minute day 1 8 . Treatment repeat every 21 day 6-10 course absence disease progression unacceptable toxicity . Treatment veliparib alone may continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Recurrent and/or metastatic breast cancer Subjects must meet least one follow two criterion : Histologically confirm primary metastatic site estrogen receptor ( ER ) negative ( le 10 % ) , progesterone receptor ( PR ) negative ( le 10 % ) , human epidermal growth factor receptor ( HER ) 2 nonover express immunohistochemistry ( IHC ) ( 0 , 1 ) nonamplified fluorescence situ hybridization ( FISH ) Confirmed BRCA1 BRCA2 mutation associate breast cancer Subjects must measurable disease , define least one lesion measure least one dimension minimum size : long diameter &gt; = 10 mm ( compute tomography [ CT ] scan slice thickness great 5 mm ) ; 10 mm caliper measurement clinical exam ; consider pathologically enlarge measurable , lymph node must &gt; = 15 mm short axis assess CT scan Subjects may number prior chemotherapy , endocrine therapy , immunologic , biologic regimen metastatic breast cancer Performance status &gt; = 60 % Karnofsky scale ( Eastern Cooperative Oncology Group [ ECOG ] = &lt; 2 ) Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 ( 1.5 x 10^9/L ) Platelets &gt; = 100,000/mm^3 ( 100 x 10^9/L ) Hemoglobin &gt; = 9.0 g/dL Serum creatinine = &lt; 1.5 x upper normal limit institution 's normal range OR creatinine clearance &gt; = 50 mL/min/1.73 m^2 subject creatinine level institutional normal Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) = &lt; 2.5 x upper normal limit institution 's normal range ; subject liver metastasis , AST and/or ALT &lt; 5 x upper normal limit institution 's normal range Bilirubin = &lt; 1.5 x upper normal limit institution 's normal range ; subject Gilbert 's syndrome may bilirubin &gt; 1.5 x upper normal limit institution 's normal range Partial thromboplastin time ( PTT ) must = &lt; 1.5 x upper normal limit institution 's normal range international normalize ratio ( INR ) &lt; 1.5 ; subject anticoagulant ( Coumadin ) PTT INR determine investigator Women childbearing potential must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 90 day follow completion therapy ; woman childbearing potential must negative serum pregnancy test within 21 day prior initiation treatment and/or confirm postmenopausal status ; criterion determine menopause include follow : prior bilateral oophorectomy ; age &gt; = 60 year ; age &lt; 60 year amenorrheic least 12 month absence chemotherapy , endocrine therapy , ovarian suppression folliclestimulating hormone ( FSH ) estradiol postmenopausal range ; Total abstinence sexual intercourse ( minimum one complete menstrual cycle ) Vasectomized partner female subject Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration Doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) Intrauterine device ( IUD ) Male subject ( include vasectomize ) whose partner pregnant might pregnant must agree use condom duration study 90 day follow completion therapy Radiation therapy nontarget lesion must complete least 2 week prior enrollment date Subjects know brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 14 day stable neurologic function prior first dose study drug Ability understand willingness sign write informed consent document Subject receive anticancer therapy include chemotherapy , immunotherapy , biologic investigational therapy within either 28 day 5 halflives target therapy ( whichever short ) , prior study drug administration ; subject receive hormone therapy , bisphosphonates , denosumab luteinizinghormonereleasing hormone ( LHRH ) agonists eligible ; subject recover within one grade level ( exceed grade 2 ) baseline follow significant adverse event toxicity attribute prior anticancer treatment exclude Subjects know hypersensitivity platinum compound vinorelbine Subjects baseline peripheral neuropathy exceeds grade 1 Clinically significant uncontrolled major medical condition ( ) include limited : Active uncontrolled infection Symptomatic congestive heart failure Unstable angina pectoris cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Any medical condition , opinion study investigator , place subject unacceptably high risk toxicity Subjects significant fluid retention , include ascites pleural effusion , may allow discretion principal investigator Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>